ACADIA Pharmaceuticals Inc. (ACAD) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं Catherine E. Owen Adams.
ACAD के पास है IPO तिथि 2004-05-27, 653 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $3.75B.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, specializing in the development and commercialization of small molecule drugs for central nervous system disorders. The company's flagship product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes multiple late-stage candidates such as pimavanserin for Alzheimer's disease psychosis and schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain management, and ACP-319 for cognitive impairment in schizophrenia and Alzheimer's disease. Founded in 1993, ACADIA remains focused on addressing significant unmet medical needs in neuropsychiatric and neurological conditions.
